J & J's $30 Billion Biotech Deal Carves Out Drug-Discovery Unit

Johnson& Johnson has agreed to acquire Actelion, Europe ’s biggest biotech company, for $30 billion, bolstering the U.S. pharmaceutical giant’s portfolio of rare-disease treatments as its top-selling drug faces new competition.
Source: WSJ.com: Health - Category: Pharmaceuticals Tags: PAID Source Type: news